RESMED Q2 RESULTSResmed (ASX: RMD) reported its Q2 FY24 results this morning and its US-listed CDIs are up around 5.4%. Here are the key numbers for Q2:Revenue of $1.16bn vs. $1.15bn consensusOperating income of $365.5m vs. $332m consensusEPS of $1.88 vs. $1.77 consensus. So it seems like a beat versus analyst expectations. We have also had the share price sell off from Ozempic fears so this should help us steadily climb back to $30+.
Ann: ResMed Announces Results for the Second Quarter of FY2024, page-4
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$30.53 |
Change
0.030(0.10%) |
Mkt cap ! $19.31B | |||
| Open | High | Low | Value | Volume |
| $30.48 | $30.61 | $30.40 | $31.60M | 1.038M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 2580 | $30.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $30.53 | 1835 | 18 |
View Market Depth
| Last trade - 14.54pm 16/07/2024 (20 minute delay) ? |
| RMD (ASX) Chart |